These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31333153)

  • 41. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.
    Yew WW; Chan CK; Chau CH; Tam CM; Leung CC; Wong PC; Lee J
    Chest; 2000 Mar; 117(3):744-51. PubMed ID: 10713001
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.
    Bouton TC; Phillips PPJ; Mitnick CD; Peloquin CA; Eisenach K; Patientia RF; Lecca L; Gotuzzo E; Gandhi NR; Butler D; Diacon AH; Martel B; Santillan J; Hunt KR; Vargas D; von Groote-Bidlingmaier F; Seas C; Dianis N; Moreno-Martinez A; Horsburgh CR
    Trials; 2017 Nov; 18(1):563. PubMed ID: 29178937
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients.
    Ahmad N; Javaid A; Syed Sulaiman SA; Afridi AK; Zainab ; Khan AH
    Am J Ther; 2018; 25(5):e533-e540. PubMed ID: 26938643
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adverse Events Associated With the Treatment of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-analysis.
    Wu S; Zhang Y; Sun F; Chen M; Zhou L; Wang N; Zhan S
    Am J Ther; 2016; 23(2):e521-30. PubMed ID: 24284652
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proportions and Risk Factors of Developing Multidrug Resistance Among Patients with Tuberculosis in China: A Population-Based Case-Control Study.
    Huai P; Huang X; Cheng J; Zhang C; Wang K; Wang X; Yang L; Deng Z; Ma W
    Microb Drug Resist; 2016 Dec; 22(8):717-726. PubMed ID: 27058017
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000-2009.
    van Altena R; de Vries G; Haar CH; de Lange WC; Magis-Escurra C; van den Hof S; van Soolingen D; Boeree MJ; van der Werf TS
    Int J Tuberc Lung Dis; 2015 Apr; 19(4):406-12. PubMed ID: 25859995
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Short-course Regimen for Subsequent Treatment of Pulmonary Tuberculosis: A Prospective, Randomized, Controlled Multicenter Clinical Trial in China.
    Yan L; Kan X; Zhu L; Xu K; Yin J; Jie L; Li Y; Yue J; Cui W; Du J; Wang L; Tan S; Jiang X; Zeng Z; Xu S; Wang L; Chen Y; He W; Gao X; Bai D; Zhao C; Yan X; Zhu Y; Fan Y; Xie L; Deng A; Zhang Q; Xiao H
    Clin Ther; 2018 Mar; 40(3):440-449. PubMed ID: 29519716
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk and outcome of multidrug-resistant tuberculosis: vitamin D receptor polymorphisms and serum 25(OH)D.
    Rathored J; Sharma SK; Singh B; Banavaliker JN; Sreenivas V; Srivastava AK; Mohan A; Sachan A; Harinarayan CV; Goswami R
    Int J Tuberc Lung Dis; 2012 Nov; 16(11):1522-8. PubMed ID: 22990231
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictors of time to unfavorable treatment outcomes among patients with multidrug resistant tuberculosis in Oromia region, Ethiopia.
    Woldeyohannes D; Assefa T; Aman R; Tekalegn Y; Hailemariam Z
    PLoS One; 2019; 14(10):e0224025. PubMed ID: 31665154
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Body mass index predictive of sputum culture conversion among MDR-TB patients in Indonesia.
    Putri FA; Burhan E; Nawas A; Soepandi PZ; Sutoyo DK; Agustin H; Isbaniah F; Dowdy DW
    Int J Tuberc Lung Dis; 2014 May; 18(5):564-70. PubMed ID: 24903794
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factors related to previous tuberculosis treatment of patients with multidrug-resistant tuberculosis in Bangladesh.
    Rifat M; Hall J; Oldmeadow C; Husain A; Hinderaker SG; Milton AH
    BMJ Open; 2015 Sep; 5(9):e008273. PubMed ID: 26351185
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Time to sputum smear and culture conversions in multidrug resistant tuberculosis at University of Gondar Hospital, Northwest Ethiopia.
    Shibabaw A; Gelaw B; Wang SH; Tessema B
    PLoS One; 2018; 13(6):e0198080. PubMed ID: 29944658
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MTBDRplus results correlate with treatment outcome in previously treated tuberculosis patients.
    Huang FL; Jin JL; Chen S; Zhou Z; Diao N; Huang HQ; Liu W; Wang Q; Weng XH; Chaisson RE; Zhang Y; Zhang WH
    Int J Tuberc Lung Dis; 2015 Mar; 19(3):319-25, i-ii. PubMed ID: 25686141
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The treatment results of patients with multidrug resistant tuberculosis and factors affecting treatment outcome.
    Karagöz T; Yazicioğlu Moçin O; Pazarli P; Senol T; Yetiş Duman D; Duman G; Saltürk C; Unal O; Halezeroğlu S
    Tuberk Toraks; 2009; 57(4):383-92. PubMed ID: 20037853
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment efficacy of drug-resistant tuberculosis in Bashkortostan, Russia: A retrospective cohort study.
    Yunusbaeva M; Borodina L; Alekseev P; Davydov R; Yunusbaev U; Sharipov R; Bilalov F; Yunusbayev B
    Int J Infect Dis; 2019 Apr; 81():203-209. PubMed ID: 30794942
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Survival time and influencing factors in multidrug-resistant tuberculosis patients in Wuhan, 2006-2014].
    Wang JJ; Zhou ML; Chen C; Wu G; Zuo YP; Ren X; Chen Z; Wang WH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Nov; 40(11):1409-1413. PubMed ID: 31838813
    [No Abstract]   [Full Text] [Related]  

  • 58. [A-cohort study on the standard short-course chemotherapy program for drug resistant tuberculosis in the rural counties in Eastern China].
    Hu Y; Jiang WL; Wang WB; Xu B
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):540-4. PubMed ID: 19040032
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hearing loss in children treated for multidrug-resistant tuberculosis.
    Seddon JA; Thee S; Jacobs K; Ebrahim A; Hesseling AC; Schaaf HS
    J Infect; 2013 Apr; 66(4):320-9. PubMed ID: 22960077
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Homeopathic treatment in addition to standard care in multi drug resistant pulmonary tuberculosis: a randomized, double blind, placebo controlled clinical trial.
    Chand KS; Manchanda RK; Mittal R; Batra S; Banavaliker JN; De I
    Homeopathy; 2014 Apr; 103(2):97-107. PubMed ID: 24685414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.